Study	Contact date	Solicited data	Response
Arbabi 2012	13‐Aug‐17	Extrapyramidal symptoms rating scale (mean and SD).	Did not respond.
Freudenreich 2009	11‐Aug‐17	ESS, FSS, PANSS, SANS, and COGBAT (mean and SD) ‐ the data are presented in a graph or as a slope. Mean and SD for weight and BMI. Method of randomisation.	Did not respond.
Kumar 2010	8‐Aug‐17	Participants leaving the study early for each group. NHRS, ESS, PANSS, IDEAS, and CGI‐I (mean scores and SD). Adverse events for each group.	Did not respond.
Leblanc 2006	11‐Aug‐17	Method of randomisation. How many participants were allocated to each group. To which group participants who left the study belonged and the reasons for leaving. Data from PANSS, CGI, SOFAS, and ESRS (mean and SD).	Information received in the form of an unpublished draft, no information was usable for this review (20 August 2017).
Lees 2017	9‐Aug‐17	Number randomised to the modafinil and placebo group in the first phase of the trial. MCCB (composite and domains) and CANTAB (mean and SD) for the first phase of the trial for each group. The number of participants with schizophrenia that left the study before the cross‐over and the group to which they were assigned. Scores (mean and SD) for the MCCB (composite and domains) and CANTAB for the first phase of the trial for each group.	Information received and used in this review (15 August 2017).
Lohr 2013	9‐Aug‐17	Data reported in a graph: SAS, PANSS (mean and SD). Data not reported in the results: AIMS, ESS, CGI‐S, BARS (mean and SD). Adverse events that occurred in both groups.	Did not respond.
Michalopoulou 2015	4‐Aug‐17	PANSS and UPSA‐B (mean score and SD) from visit 14; we used data from visit 16.	Did not respond.
Prasuna 2015	17‐Aug‐17	BPRS, CGI‐S, EDD (mean and SD). List of adverse events.	Did not respond.
Sevy 2005	12‐Aug‐17	Method of randomisation and allocation. The list of adverse events (only the adverse events for the modafinil group are reported in the report). SANS total (mean and SD).	Did not respond.
Spence 2005	16‐Aug‐17	The group to which the participant who relapsed belonged.	Information received and used in this review (18 August 2017).
Turner 2004	14‐Aug‐17	CANTAB (mean and SD) for the first phase of the trial.	Did not respond.